EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025

Yoshiko Mizukawa, Tetsuo Shiohara

Allergology International · 2025-07 · 74 (3) · 372-379

DOI: 10.1016/j.alit.2025.03.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergology International, 2025-07. Verfasst von Yoshiko Mizukawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan. Electronic address: ymizu@ks.kyorin-u.ac.jp. Hauptthemen laut MEDLINE: Drug Hypersensitivity Syndrome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug reaction characterized by a range of clinical manifestations. These range from mild cases resolving upon cessation of the causative drug to severe cases involving complex disease progression and potential fatality. A hallmark of DIHS/DRESS is the sequential reactivation of herpesviruses, particularly human herpesvirus 6 (HHV-6), during the disease course, contributing to recurrent symptoms. Viral reactivation can lead to critical complications, including infectious DIHS/DRESS-associated complications (iDACs) and autoimmune sequelae (aDACs). Managing DIHS/DRESS remains challenging due to its complexity, requiring precise prediction and tailored treatment strategies. Recent studies suggest that early-stage classification using the DIHS/DRESS Severity (DDS) score may help identify refractory cases, including DACs. Furthermore, early intervention with anti-cytomegalovirus (anti-CMV) therapy can mitigate iDACs caused by CMV reactivation, preventing progression to severe CMV-related diseases. Long-term follow-up is crucial, as aDACs can manifest even 3 years postonset. Serial monitoring is recommended, particularly in patients treated with intravenous immunoglobulin or corticosteroid pulse therapy, which are recognized risk factors for aDAC development. This review highlights DIHS/DRESS management strategies, focusing on its clinical features, the role of viral reactivation, and therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Hypersensitivity SyndromeHumansDisease ManagementHerpesvirus 6, HumanVirus Activation

Stichwörter der Autor:innen

Autoimmune sequelaeDIHS/DRESS management strategiesDrug reaction with eosinophilia and systemic symptoms (DRESS)Drug-induced hypersensitivity syndrome (DIHS)Herpesvirus reactivation

Autor:innen und Institutionen

  • Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan. Electronic address: ymizu@ks.kyorin-u.ac.jp.
  • Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.

Förderung

  • Ministry of Health, Labour and Welfare
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science

Zitieren

APA

Mizukawa, Y., & Shiohara, T. (2025). Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025. Allergology International, 74(3), 372-379. https://doi.org/10.1016/j.alit.2025.03.007

Vancouver

Mizukawa Y, Shiohara T. Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025. Allergology International. 2025;74(3):372-379. doi:10.1016/j.alit.2025.03.007

BibTeX
@article{Mizukawa2025,
  author = {Mizukawa, Yoshiko and Shiohara, Tetsuo},
  title = {Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025},
  journal = {Allergology International},
  year = {2025},
  volume = {74},
  number = {3},
  pages = {372--379},
  doi = {10.1016/j.alit.2025.03.007}
}
Kostenlos starten →